Artiva Biotherapeutics logo
Artiva Biotherapeutics
ARTV | NASDAQ
Chart Builder DCF Calculator
$3.96
-$0.05 (-1.25%)
At close: Nov 16, 2026, 4:00 PM ET
$3.94
-$0.02 (-0.51%)
After-hours: Nov 16, 2026, 7:30 PM ET

Artiva Biotherapeutics Company Profile

Company profile explained

Company Profile

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Key Executives

Name Position
Fred Aslan CEO, Principal Financial & Accounting Officer and Director
Jennifer Kinsbruner Bush Chief Operating Officer
Andrew Cronauer VP, General Counsel & Corporate Secretary
Benjamin Dewees Senior Vice President of Regulatory Affairs
Christopher Horan Chief Technical Operations Officer
David Moriarty Senior Vice President of Clinical Operations
Feng Xu Senior Vice President of Biometrics
Gines Diego Miralles President and Head of Research & Development
Heather Raymon Senior Vice President of Research & Early Development
Nicholas Veomett Vice President of Corporate Development
Peter Flynn Co-Founder & Strategic Advisor

Latest SEC Filings

Date Type Title
Oct 27, 2026 8-K Current Report
Oct 07, 2026 4 Filing
Oct 06, 2026 4 Filing
Oct 06, 2026 4 Filing
Oct 06, 2026 4 Filing
Oct 06, 2026 4 Filing
Sep 15, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 14, 2026 4 Filing
View All SEC Filings ➞
Artiva Biotherapeutics
Artiva Biotherapeutics logo
Country United States
IPO Date Jul 19, 2024
Industry Biotechnology
Sector Healthcare
Employees 115
CEO Fred Aslan

Contact Details

5505 Morehouse Drive San Diego, California 92121 United States

Stock Details

Ticker Symbol ARTV
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001817241
CUSIP Number 04317A107
ISIN Number US04317A1079
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.